A practical reference on regulatory status: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-10. Anything still debated is marked as such rather than presented as settled.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
"DEA Schedules of Controlled Substances: Rescheduling of Hydrocodone Combination Products From Schedule III to Schedule II". Federal Register. 6 October 2014. Archived from the original on 10 August 2016. Retrieved 6 October 2014.
=== Anthrax toxin delivery === Moving peptide and protein therapeutics through the plasma membrane of cells has been made more efficient through the use of a platform made from the anthrax lethal toxin (PA/LFN), which arises from the bacterium Bacillus anthracis. Pentelute's lab took more than two decades to develop this delivery vehicle. His studies of intracellular delivery help us understand the movements of proteins and to explore different biological functions within cells. Previous techniques to transport molecules through the plasma membrane of mammalian cells proved to be less effective and required higher concentrations of substance to be useful. When compared, the anthrax lethal toxin based delivery method was proved to transport proteins faster and more efficiently. Through the use of chemical ligation (NCL) and enzyme-mediated ligation using Sortase A (SrtA), non-native cargos that contain functionalities that don't naturally occur can be created that provide benefits such as increased stability to internal degradation of the cell, added use of affinity handles, and adjusted connective affinities to target molecules. These fusions also attach the resulting peptides to the N-terminus of the native lethal factor (LFN).
It has a varying consistency depending on manufacturing methods, cutting agents, and moisture levels, from tarry goo in the unrefined form to a uniform, light-brown powder when further processed and cut with a variety of agents. One of the more notable compounds commonly added to heroin is lactose.
The territory was subsequently claimed and settled by Portugal, which founded the country's first city, São Vicente, in 1532 and imported enslaved Africans to work on plantations. Brazil remained a colony until 1815, when it was elevated to a united kingdom with Portugal after the transfer of the Portuguese court to Rio de Janeiro. Prince Pedro of Braganza declared Brazilian independence in 1822 and, after waging a war against Portugal, established the Empire of Brazil. The country's first constitution in 1824 established a bicameral legislature and enshrined principles such as freedom of religion and the press; slavery was gradually abolished until its final abolition in 1888. Brazil became a presidential republic following a military coup d'état in 1889. An armed revolution in 1930 ended the First Republic and brought Getúlio Vargas to power. Vargas' self-coup in 1937 ushered the authoritarian Estado Novo, in which he oversaw Brazil's involvement in World War II. Democracy was restored after Vargas' ousting in 1945. An authoritarian military dictatorship emerged in 1964 with support from the United States and ruled until 1985, after which civilian governance resumed. Brazil's current constitution, enacted in 1988, defines it as a democratic federal republic. Brazil is a regional and middle power, and has been described as a rising global power.
Sources: en.wikipedia.org
== Interactions == Drug interactions with drotrecogin have not been systematically studied in patients with severe sepsis. Caution should be exercised when using other drugs that affect hemostasis concomitantly with drotrecogin (e.g. aspirin, warfarin, clopidogrel). However, the use of low dose prophylactic Heparin did not affect safety when given concurrently with drotrecogin.
The 2021 edition of Fastlane would be the beginning of WWE phasing out the standalone WWE Network, with the company partnering with other platforms to distribute its content. Beginning with that edition of Fastlane in the United States, events began airing on NBCUniversal's streaming service, Peacock, following a merger of the American WWE Network under Peacock in March that year. The standalone version of the American WWE Network shut down on April 4. Over the next couple of years, other countries would see their own version of the WWE Network merge under other services. In Indonesia, the WWE Network merged under Disney+ Hotstar in January 2022, followed by a merger under Disney+ in the Philippines in November that year, while in Australia, it merged under Binge in January 2023 and then Abema in Japan that October. With this increased emphasis of digital platforms over traditional PPV outlets, WWE began to refer to all PPV and livestreaming events as "Premium Live Events" (PLEs), starting with the Day 1 event on January 1, 2022. In January 2025, the majority of the countries that still had the WWE Network merged under Netflix, with only a small number of countries maintaining the WWE Network due to pre-existing contracts. Beginning with Wrestlepalooza in September 2025, ESPN's direct-to-consumer streaming service assumed the streaming rights for main roster PLEs in the United States as part of a five-year deal following WWE's contract with Peacock. Also as part of the deal, select events also air on ESPN's linear channels.
Risk of developing CJD increases with age. CJD incidence was 3.5 cases per million among those over 50 years of age between 1979 and 2017. Approximately 85% of CJD cases are sporadic, and 10–15% of CJD cases are due to inherited mutations of the prion protein gene. CJD deaths and age-adjusted death rate in the United States indicate an increasing trend in the number of deaths between 1979 and 2017. Although not fully understood, additional information suggests that CJD rates in nonwhite groups are lower than in whites. While the mean onset is approximately 67 years of age, cases of sCJD have been reported as young as 17 years and over 80 years of age. Mental capabilities rapidly deteriorate and the average amount of time from onset of symptoms to death is 7 to 9 months. According to a 2020 systematic review on the international epidemiology of CJD:
Californium is a synthetic chemical element; it has symbol Cf and atomic number 98. It was first synthesized in 1950 at Lawrence Berkeley National Laboratory (then the University of California Radiation Laboratory) by bombarding curium with alpha particles (helium-4 ions). It is an actinide element, the sixth transuranium element to be synthesized, and has the second-highest atomic mass of all elements that have been produced in amounts large enough to see with the naked eye (after einsteinium). It was named after the university and the U.S. state of California. Two crystalline forms exist at normal pressure: one above and one below 900 °C (1,650 °F). A third form exists at high pressure. Californium slowly tarnishes in air at room temperature. Californium compounds are dominated by the +3 oxidation state. The most stable of californium's twenty known isotopes is californium-251, with a half-life of 898 years. This short half-life means the element is not found in significant quantities in the Earth's crust. 252Cf, with a half-life of about 2.645 years, is the most common isotope used and is produced at Oak Ridge National Laboratory (ORNL) in the United States and Research Institute of Atomic Reactors in Russia. Californium is one of the few transuranium elements with practical uses. Most of these applications exploit the fact that certain isotopes of californium emit neutrons. For example, californium can be used to help start up nuclear reactors, and it is used as a source of neutrons when studying materials using neutron diffraction and neutron spectroscopy.
Medical preparations of insulin mix the peptide hormone with preservatives that adjust the pH and delay denaturation and absorption. Insulin analogues retain the hormone's function while providing improved absorption and biochemical activity. characteristics not currently possible with subcutaneously injected insulin proper. Insulin lispro, insulin aspart, and insulin glulisine are analogues that are rapidly absorbed to mimic real beta cell-produced insulin, while insulin detemir and insulin glargine are steadily absorbed to avoid a rapid decline in insulin action. However, meta-analyses conducted by Cochrane in 2005, Germany's Institute for Quality and Cost Effectiveness in the Health Care Sector [IQWiG] in 2007, and Canadian Agency for Drugs and Technology in Health (CADTH) also in 2007 have consistently shown that insulin analogues provide no clinical advantage over conventional insulin. However, insulin analogues are more temperature-resistant than human insulin, so they are preferred for clinical use in regions with limited refrigeration and extreme heat. Commonly used types of insulin are differentiated by the speed of their biochemical activity. Fast/rapid-acting insulin includes insulin analogues aspart, lispro, and glulisine. These begin to work within 5 to 15 minutes and are active for 3 to 4 hours. Most insulins form hexamers, which delay entry into the blood in active form; these analog insulins do not but have normal insulin activity.
Sources: en.wikipedia.org
=== Venom-induced pathology === As a consequence of the numerous activities the enzyme participates in, it could be deduced that there is likely some enzymatic function regarding the complex network of venom toxin activities. Recent findings suggest a more defined role for LAAO in venom-induced tissue damage. One study demonstrated that LAAO from Bothrops atrox venom causes cell death in human keratinocytes via a sequence of autophagy, apoptosis, and necrosis, driven primarily by hydrogen peroxide production. In vivo, co-injection of the antioxidant N-acetyl cysteine (NAC) significantly reduced dermonecrosis in mice, implicating LAAO-generated oxidative stress in envenomation pathology.
Data from Erection and Maintenance Manual for P-51D and P-51K, P-51 Tactical Planning Characteristics & Performance Chart, The Great Book of Fighters, and Quest for PerformanceGeneral characteristics Crew: 1 Length: 32 ft 3 in (9.83 m) Wingspan: 37 ft 0 in (11.28 m) Height: 13 ft 4.5 in (4.077 m) tail wheel on ground, vertical propeller blade Wing area: 235 sq ft (21.8 m2) Aspect ratio: 5.83 Airfoil: NAA/NACA 45–100 Empty weight: 7,635 lb (3,463 kg) Gross weight: 9,200 lb (4,173 kg) Max takeoff weight: 12,100 lb (5,490 kg) Fuel capacity: 269 US gal (224 imp gal; 1,020 L) Zero-lift drag coefficient: 0.0163 Drag area: 3.80 sqft (0.35 m²) Powerplant: 1 × Packard (Rolls-Royce) V-1650-7 Merlin 12-cylinder liquid cooled engine, 1,490 hp (1,110 kW) at 3,000 rpm; 1,720 hp (1,280 kW) at WEP Propellers: 4-bladed Hamilton Standard constant-speed, variable-pitch, 11 ft 2 in (3.40 m) diameter Performance
Acid guanidinium thiocyanate-phenol-chloroform extraction (abbreviated AGPC) is a liquid–liquid extraction technique in biochemistry and molecular biology. It is widely used for isolating RNA (as well as DNA and protein in some cases). This method may take longer than a column-based system such as the silica-based purification, but has higher purity and the advantage of high recovery of RNA. Furthermore, an RNA column is typically unsuitable for purification of short (<200 nucleotides) RNA species, such as siRNA, miRNA and tRNA. It was originally devised by Piotr Chomczynski and Nicoletta Sacchi, who published their protocol in 1987. The reagent is sold by Sigma-Aldrich by the name TRI Reagent; by Invitrogen under the name TRIzol; by Bioline as Trisure; and by Tel-Test as STAT-60.
Conus geographus, part of the Encyclopædia Romana by James Grout. "Gastridium geographus". Gastropods.com. Retrieved 16 January 2019. Cone Shells - Knights of the Sea Photos of Conus geographus in the Sealife Collection
Tribhuvan University was the first public university in Nepal. It operates through six different institutes and is affiliated with various colleges. There are government-funded Purbanchal University and Pokhara University.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.